• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Oyster point

Quote
anonymous said:
looked it up. Turns out you’re an idiot. Label says “Basel tear”. Guess that proves “reflex” is false. Also found their data out to 19 months and it showed it was still working. May want to do a little “looking up” yourself
Click to expand...

No one knows if it stimulates basal or reflex tearing. The basal comment in the label is speculation as it subsequently says: “The exact mechanism of action is unknown at this time.”
 




anonymous said:
No one knows if it stimulates basal or reflex tearing. The basal comment in the label is speculation as it subsequently says: “The exact mechanism of action is unknown at this time.”
Click to expand...

wrong! Tear studies show “basal tear” which is what the FDA reviewed to allow it in the label. They don’t let you just say anything you want in a label. The moa comment is in reference to stimulation pathway.
 




anonymous said:
wrong! Tear studies show “basal tear” which is what the FDA reviewed to allow it in the label. They don’t let you just say anything you want in a label. The moa comment is in reference to stimulation pathway.
Click to expand...

please post a link to the clinical trial where they dosed with the nasal spray drug a d proved basal tearing increased. Wait, that doesn’t exist. The evidence is secondary and inconclusive. FDA lets marketing BS slip into the label for unknown MOAs all the time.
 




Stop arguing and just look at the stock price. Nothing but south since approval. This company is in for trouble. Loaded with debt and with the market shorting the launch while an inexperienced management team tries to sell a piece of crap product with glossy marketing and zero coverage. Don’t stake your careers on nonsense. Just look at what Kala is going through. Join Novartis and sell the real money maker, Xiidra.
 




anonymous said:
Before you join this dumpster fire, consider the following:
- The CEO essentially got a PhD from the University of Phoenix and has never any kind of business
- The biggest leadership role he ever had was head of Med Affairs at a crappy company that went bankrupt while he was there
- The founder and first chairman of this company M Ackerman quit as soon as possible post IPO so that he could dump his shares
- The predecessor technology was a complete disaster and discontinued by AbbVie once they bought Allergan
- Their product is no better at wetting your eyes than plucking nose hairs and will not get coverage
- The drug effects your brain and has a black box warning for suicidal thoughts; not what anyone wants to spray up your nose
- The drug burns your nose and throat and makes you sneeze uncontrollably with every administration, and the company is hiding those facts
- The CCO was rejected by Shire, Takeda, and Novartis before ending up here
…I could go on. Stick with the better companies out there is my opinion. Kala is another option as is EyePoint, or you can stick to Novartis, AbbVie, Santen, B&L.
Click to expand...
Smartest and most honest information on the internet . You’re 1000% correct and nobody can argue with any of your points
 




anonymous said:
Stop arguing and just look at the stock price. Nothing but south since approval. This company is in for trouble. Loaded with debt and with the market shorting the launch while an inexperienced management team tries to sell a piece of crap product with glossy marketing and zero coverage. Don’t stake your careers on nonsense. Just look at what Kala is going through. Join Novartis and sell the real money maker, Xiidra.
Click to expand...
 




anonymous said:
Stop arguing and just look at the stock price. Nothing but south since approval. This company is in for trouble. Loaded with debt and with the market shorting the launch while an inexperienced management team tries to sell a piece of crap product with glossy marketing and zero coverage. Don’t stake your careers on nonsense. Just look at what Kala is going through. Join Novartis and sell the real money maker, Xiidra.
Click to expand...

Absolutely agree
 




This place oozes desperation…it’s not even a “me too” because what’s out there is better on many levels, including personnel

nobody wants to see those old buffoons in beards awkwardly prancing around on stage for their own delight because it certainly wasn’t for our’s. Self-serving for old men who need to feel good about themselves and do so by getting it from people faking it who are on the company payroll. Rather than rehearsing with their beards, pun intended for one, they should be focused on selling this POS snake oil and have us taken seriously. If not, then go to your retirement community and take your Rituxan and let someone else with leadership and focus help this sinking ship.
 








anonymous said:
Stop arguing and just look at the stock price. Nothing but south since approval. This company is in for trouble. Loaded with debt and with the market shorting the launch while an inexperienced management team tries to sell a piece of crap product with glossy marketing and zero coverage. Don’t stake your careers on nonsense. Just look at what Kala is going through. Join Novartis and sell the real money maker, Xiidra.
Click to expand...

what a bunch of crap. Sounds like suckvartis is afraid. Should be!
 




anonymous said:
This place oozes desperation…it’s not even a “me too” because what’s out there is better on many levels, including personnel

nobody wants to see those old buffoons in beards awkwardly prancing around on stage for their own delight because it certainly wasn’t for our’s. Self-serving for old men who need to feel good about themselves and do so by getting it from people faking it who are on the company payroll. Rather than rehearsing with their beards, pun intended for one, they should be focused on selling this POS snake oil and have us taken seriously. If not, then go to your retirement community and take your Rituxan and let someone else with leadership and focus help this sinking ship.
Click to expand...

sounds like a disgruntled marketer who needs to move on. We all know who you are. Time for you to go.
 








Wow, OYST announces that their Onset-2 trial is published in a peer reviewed journal and the stock drops like a rock, down -10%. Tells you everything you need to know right there. No more hiding behind glossy charts and half truths. 99% of people who used the drug experienced adverse events. What a piece of trash product.
 








Well well well. Let this be a lesson kiddos. When a big power or big pharma feels threatened they bring out lies and shit to trash whatever is threatening them. Don’t believe this garbage. Go ahead, try Tyrvaya for your self. You’ll see. It works and theirs doesn’t. PLEASE! Try it.
 








anonymous said:
Well well well. Let this be a lesson kiddos. When a big power or big pharma feels threatened they bring out lies and shit to trash whatever is threatening them. Don’t believe this garbage. Go ahead, try Tyrvaya for your self. You’ll see. It works and theirs doesn’t. PLEASE! Try it.
Click to expand...

NVS sucks. hope oyster kicks their ass
 
















Top Bottom
Back
Quote